Your session is about to expire
← Back to Search
Pembrolizumab for Lymphoma
Study Summary
This trial is testing whether combining the immunomodulatory agent pembrolizumab with low-dose radiotherapy can help treat patients with relapsed or refractory non-Hodgkin lymphoma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Group 1: Pembrolizumab and Radiation Therapy
Frequently Asked Questions
What are the possible dangers of Pembrolizumab?
"Pembrolizumab has received a score of 2 for safety. This is due to the fact that, while there is some evidence supporting its safety from Phase 2 trials, there is no data currently backing its efficacy."
What are the main diseases that Pembrolizumab helps to fight?
"Pembrolizumab is a medication that oncologists often prescribe to treat malignant neoplasms. It can also be used as second-line therapy for unresectable melanoma, microsatellite instability high, and disease progression after chemotherapy."
Does Pembrolizumab boast a solid clinical trial history?
"Pembrolizumab is being investigated in 1000 different clinical trials, 122 of which are currently ongoing. The majority of these active investigations are Phase 3 studies. Although the largest concentration of research is based in Houston, Texas; there are 36053 total locations running Pembrolizumab trials."
Are there any current vacancies for participants in this trial?
"According to the latest information on clinicaltrials.gov, this trial is still recruiting patients. It was originally posted on December 1st, 2020 and updated for the last time on July 11th, 2020."
How many people are able to enroll in this research project?
"Yes, according to the most recent information from clinicaltrials.gov, this trial is still recruiting patients. This particular study was first posted on December 1st, 2022 and last updated on July 11th, 2022. They are aiming to enroll 40 patients at a single location."
Share this study with friends
Copy Link
Messenger